Distributive sharing among HIV-HCV co-infected injecting drug users: the preventive role of trust in one's physician by Jauffret Roustide, Marie et al.
Distributive sharing among HIV-HCV co-infected
injecting drug users: the preventive role of trust in one’s
physician
Marie Jauffret Roustide, Julien Cohen, Isabelle Poisot-Martin, Bruno Spire,
Michael Gossop, Patrizia Carrieri
To cite this version:
Marie Jauffret Roustide, Julien Cohen, Isabelle Poisot-Martin, Bruno Spire, Michael Gos-
sop, et al.. Distributive sharing among HIV-HCV co-infected injecting drug users: the pre-
ventive role of trust in one’s physician. AIDS Care, Taylor & Francis (Routledge), 2011,
<10.1080/09540121.2011.596515>. <hal-00719816>
HAL Id: hal-00719816
https://hal.archives-ouvertes.fr/hal-00719816
Submitted on 21 Jul 2012
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

For Peer Review Only
 
 
 
 
 
 
 
Distributive sharing among HIV-HCV co-infected injecting 
drug users: the preventive role of trust in one’s physician 
 
 
Journal: 
AIDS Care - Psychology, Health & Medicine - Vulnerable Children 
and Youth Studies 
Manuscript ID: AC-2010-11-0621.R2 
Journal Selection: AIDS Care 
Keywords: 
drug users, high-risk behaviours, co-infection HIV/HCV, trust in 
physician 
  
 
 
 
http://mc.manuscriptcentral.com/ac-phm-vcy
Health Sciences
For Peer Review Only
Table I : Factors associated with lending of injection equipment among IDU patients infected with HIV and HCV: univariate and 
multivariate analysis using logistic regression model based on GEE  (N=224)   
   Univariate analysis Multivariate analysis 
 Number of visits 
(%) or median 
[IQR] 
Number of 
patients 
OR (95% CI) p-value AOR (95% CI) p-value 
Female gender 180 (33.5) 71 1.58 (0.89;2.81) 0.12   
Stable partner 347 (64.5) 170 1.03 (0.62;1.71) 0.92   
Agea 35 [31-38]  0.56 (0.32;0.98) 0.04 0.52 (0.30;0.91) 0.02 
Having children 206 (38.5) 94 0.69 (0.38;1.24) 0.21   
High school certificate 65 (12.4) 25 0.46 (0.15;1.40) 0.17   
Employment 107 (20.0) 54 0.25 (0.09;0.66) 0.001 0.27 (0.10;0.69) 0.006 
Home owner or rent 354 (65.8) 157 0.92 (0.54;1.57) 0.76 
  
Good housing 
conditionsb 
421 (78.5) 181 0.99 (0.54;1.81) 0.86 
  
Heavy alcohol usec 93 (17.3) 56 1.80 (0.99;3.26) 0.05   
Hazardous alcohol used 121 (22.7) 81 1.72 (1.00;2.95) 0.05   
Cocaine use 269 (50.1) 121 2.32 (1.38;3.89) 0.002 2.37 (1.38;4.06) 0.002 
Heroin use 374 (69.7) 194 0.87 (0.51;1.47) 0.60 
  
Daily cannabis use 302 (56.2) 149 1.58 (0.95;2.62) 0.10   
Psychotropic drug 
consumption 
366 (68.0) 175 1.51 (0.86;2.65) 0.15   
More than 20 cigarettes 
a day 
346 (64.3) 168 0.82 (0.49;1.38) 0.46 
  
Experience of 
withdrawal symptoms 
181 (33.6) 119 1.60 (0.99;2.58) 0.06   
High support from stable 
partnere 
203 (39.0) 112 0.68 (0.40;1.18) 0.17   
High support from 
familye 
243 (45.5) 125 0.61 (0.36;1.02) 0.06   
High support from 
friendse 
126 (23.6) 82 0.61 (0.33;1.14) 0.12   
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Depressive symptomsf 373 (69.5) 181 1.66 (0.91;3.02) 0.10   
Opioid substitution 
treatment 
- No OST 
- Buprenorphine 
treated 
- Methadone treated 
 
 
194 (36.3) 
184 (34.5) 
 
156 (29.2) 
 
 
121 
91 
 
73 
 
 
 
0.99 (0.53;1.84) 
 
1.71 (0.93;3.14) 
 
 
 
0.98 
 
0.08 
  
Benzodiazepines use 263 (48.9) 146 1.51 (0.92;2.46) 0.10   
Anxiolytics use* 306 (56.9) 143 1.06 (0.63;1.76) 0.83 
  
Hypnotics use 198 (36.8) 112 1.79 (1.08;2.97) 0.02   
Neuroleptics use 30 (5.6) 23 3.63 (1.67;7.88) 0.001   
Barbiturate use 58 (10.8) 43 0.65 (0.19;1.12) 0.01   
Trust in physiciang 418 (78.4) 178 0.51 (0.29;0.92) 0.03 0.51 (0.29;0.92) 0.03 
Number of years since 
first drug injectiona 
15 [13-18]  0.74 (0.41;1.32) 0.31 
  
Number of years since 
first positive HIV testa 
10 [7-12]  1.16 (0.57;2.38) 0.69 
 
 
Undetectable viral load 131 (24.8) 63 1.26 (0.73;2.18) 0.42 
 
 
CD4 cell count per 
mm3<500 
349 (65.4) 169 0.96 (0.58;1.60) 0.89 
 
 
     
 
 
HIV clinical stage 
- A (ref) 
- B 
- C 
 
263 (49.0) 
245 (45.6) 
29 (5.4) 
 
146 
97 
13 
 
 
1.08 (0.63;1.85) 
0.72 (0.18;2.88) 
 
 
0.77 
0.65 
 
 
  
a
 For 10 years increase 
b
 Good housing conditions were defined as the rank 3 and 4 (quite or very comfortable vs. uncomfortable or low comfort) using a four-point 
Likert scale. 
c
 Heavy alcohol use was defined as alcohol consumption > 150 units per month for men and > 100 units per month for women. 
d
 Binge drinking was defined as drinking more than four alcohol units on any one occasion. 
e
 Support from partner, family and friends was measured on a four-point Likert scale and individuals with high support (rank 4) were compared 
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to those with lower ranks (no, limited or moderate support from the partner). 
f Patients were defined with depressive symptoms if CES-D>17 for men and >23 for women. 
* other than benzodiazepines 
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Distributive sharing among HIV-HCV co-infected injecting drug users: the 
preventive role of trust in one’s physician 
  
 
Abstract 
This study, based on data from the MANIF 2000 cohort study, investigates the 
relationship between the lending of injecting equipment, drug use and experience with 
HIV care.  The sample comprised 224 HIV-HCV-coinfected patients who reported 
having injected drugs in the previous 6 months and their 538 visits to clinical services.  
Longitudinal data were collected for medical status, and self-reported risk behaviors. A 
logistic regression GEE model was used to identify correlates of distributive sharing. 
After multiple adjustment, patients who reported trust in physicians were significantly 
less likely to report lending injection equipment while cocaine users were at increased 
risk.  Promoting dialogue between physicians and IDUs may play an important role in 
HIV-HCV positive prevention.  
 
Key words : drug users, high-risk behaviors, co-infection HIV/HCV, trust in physician 
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Background 
Even in countries that have adopted needle exchange programs (NEP) and expanded access to 
opioid substitution treatment (OST), the prevalence of HCV in injecting drug users (IDUs) 
remains extremely high (60-70%) and even higher in those HIV-infected through drug use 
(Jauffret-Roustide et al., 2009). Among IDUs, HCV, like HIV, is mainly transmitted through 
needle sharing. However, HCV  is more easily transmitted than HIV because its prevalence is 
greater, it is more resistant to desiccation (Centers for Disease Control and Prevention", 1998) 
and it is also linked to the sharing of drug paraphernalia (water, filter, spoon) (Hagan et al., 
2001; McCoy, Metsch, Chitwood, Shapshak, & Comerford, 1998). HCV infection can 
consequently occur after substantially less injection and fewer sharing episodes (Hahn et al., 
2002; Miller et al., 2002). All around the world, the current harm reduction (HR) policy seems 
to have been less effective in controlling HCV than HIV and consequently HR packages for 
controlling HCV are under evaluation. Targeting HIV-HCV co-infected patients’ risk 
behaviors is important, as interventions on this population may have a major role in 
controlling the spread of both HIV and HCV. Risks involved in injection practices greatly 
contribute to the spread of blood-borne transmitted diseases among IDUs (Alter, 2006) .   
 
A range of interventions has been implemented to reduce the spread of blood-borne diseases 
among IDUs.  
Even though HR interventions have been found to have an impact upon HIV prevalence and 
incidence among IDUs (Cazein et al., 2008; Des Jarlais et al., 2005; Van Den Berg, Smit, Van 
Brussel, Coutinho, & Prins, 2007), some HIV positive IDUs continue to engage in high-risk 
behaviors. There is an urgent need to develop and strengthen effective interventions for HIV-
positive IDUs who are still engaged in high-risk behaviors.    
The French HR policy has provided expanded and free access to OST (70% coverage), NEP  
(Emmanuelli & Desenclos, 2005) but HCV prevalence among IDUs is still high (Jauffret-
Roustide et al., 2006). 
While several studies document incidence rates of HCV and the pattern of risk factors, little is 
known about HIV-HCV risk practices in co-infected IDUs. Also, few studies take account of 
the serological status of IDUs involved in high-risk behaviors, and fewer studies have  
focused on distributive sharing among HIV/HCV coinfected IDUs (Metsch et al., 2007).  
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The present study used data from the MANIF 2000 cohort of HIV-HCV co-infected patients 
to identify whether experience with HIV care and access to ART, social demographic 
characteristics and specific use of drugs could influence the practice of distributive sharing 
among active IDUs.  The study also investigated the role of the physician, and specifically of 
the trust in physician among HIV-HCV co-infected IDUs in relation to high-risk behaviors. 
 
Method  
Sample and setting 
The sample comprised 224 HIV-HCV co-infected patients who reported having injected drugs 
at least once in the 6 months prior to interview. Only visits where patients reported having 
injected were included in the data analysis (538 visits).  
The sample was drawn from the MANIF 2000 cohort which enrolled 467 patients who were 
HIV-infected through injection drug use between July 1995 and May 1998. Patients were 
enrolled in hospital-based outpatient HIV clinics and followed-up until 2007. Inclusion 
criteria for enrolment in the cohort included only patients with a CD4+ cell count >300/ul in 
the last visit prior to enrolment and with clinical stages A or B. This cohort was designed to 
focus on social and behavioral aspects of HIV-positive IDUs and particularly on their access 
and adherence to ART. 
All individuals who agreed to be interviewed signed an informed consent form, approved with 
the study protocol by the French committee responsible for the evaluation of work involving 
human subjects. 
 
Procedure 
Data collection (every 6 months) was based on medical records, a face-to-face interview and a 
self-administered questionnaire. Clinical data, including CD4 cell count, HIV viral load and 
HIV clinical stage were derived from clinical records. The face-to-face interview was 
administered by trained nurses who gathered psychosocial information (social support and 
patient-physician relationship) as well as information about patients’ personal experience with 
HIV infection and care. The questionnaire collected socio-demographic data, year of first 
drug injection, incarceration, several items about substance use and at-risk behaviors. All the 
data collected referred to the 6 months prior to the given visit.  
Injecting drug use at any given visit thereafter was defined as the injection of heroin or 
morphine, psychotropic drugs, cocaine, buprenorphine or any other drugs in the 6 months 
before that visit.  
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Depressive symptoms were detected using the French version of the Center for 
Epidemiological Studies Depression Scale (CES-D) (Fuhrer & Rouillon, 1989). Although 
CES-D cannot be considered as a clinical tool for diagnosing depression, patients were 
considered to present depressive symptoms if their CESD score was greater than 17 (for men) 
or greater than 23 (for women) (Radloff, 1977).   
A measure of the trust between physicians and their patient was calculated using a single item 
using a 5-point Likert scale to score patient agreement with different suggested levels of trust 
in their physician. In the data analysis, the variable was dichotomized to contrast individuals 
reporting very high and high agreement vs those reporting moderate, low or very low 
agreement.  
 
In order to minimize the risk of under-reporting, the definition of the outcome variable of 
“distributive sharing at a given visit” was based on several questions: 
1. Having lent syringe/needle or other paraphernalia at least once in the 6 previous months 
before the visit 
2. Having lent needle/syringe to someone else during their last injection if it occurred in the 6 
months prior to the visit 
3. Having lent other paraphernalia (filter, spoon) to someone else during their last injection if 
it occurred in the 6 months prior to the visit. 
 
Statistical methods 
To determine factors associated with distributive sharing, only visits of those individuals 
reporting active injection during follow-up were included.  A logistic regression GEE model  
was used to assess the independent effect of  patient-physician relationship and individual 
characteristics on distributive sharing.  
Variables were considered eligible for entering the final models if in their p value was <0.25 
in the univariate analysis. The final model was built using a backward procedure based on the 
log likelihood ratio test with p<0.05.    
All the analyses were performed using Stata version 10.1. 
 
Results 
Among the 224 co-infected patients who also reported having injecting drugs at least once 
during the whole follow-up (4 years on average, 993.5 person-years), 166 reported injection 
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cessation for at least one year during follow-up. The 243 individuals who were excluded 
because they never reported injection over the whole observation period, had longer duration 
of follow-up (6 years on average, 1638.5 person-years). 
  
The 224 patients in the study sample were mainly men (68.3%, 153 patients), median [IQR] 
patient age was 35 [32–38] years. Thirty eight were employed at enrolment (17.1%) and 25 
(11.5%) had a high school certificate but the majority (30%) had 9 years of education and 
25% did not have a primary school certificate.. At enrollment in the cohort, 142 (63.4%) were 
living in a stable relationship and 138 (61.6%) reported being the owner or tenant of their 
house. At enrollment, median [IQR] time since first injection was 14 [12–17] years, and 168 
(75.3%) presented depressive symptoms. Sixty-nine patients (30.8%) started ART during 
follow-up. 
 
Among the 224 patients accounting for 538 visits where injection 6 months prior the visit was 
reported, 157 (71%) reported having shared injecting equipment in 282 visits (54%) ; 
distributive sharing was reported by 57 patients (25%) in 82 visits (15%) and borrowing 
injection equipment was reported by 119 patients (53%) at 173 visits (32%). 
 
The distribution of the main characteristics and behaviors observed at the selected visits and 
the associations between such characteristics and distributive sharing are presented in Table I.  
When focusing on substance use behaviors, individuals reporting injection at these visits also 
reported, respectively, heroin or cocaine use in 70% and 50% of the selected visits while 
benzodiazepine in 49% of the visits. Experience of withdrawal symptoms was reported in 
34% of visits.After adjustment for socio-demographic factors (age and employment), 
individuals reporting cocaine use were at increased risk of distributive sharing. Conversely, 
individuals reporting trust in physicians were significantly less likely to report lending 
injection equipment (Table I). However the adjustment for IMR (i.e. for inequity in ART 
access) did not affect the relationship between trust in physicians and distributive sharing.  
 
It is interesting to note that trust in physicians was also associated with high adherence 
(p=0.001) and better virological outcomes (undetectable viral load p=0.05), but not with 
“systematic condom use in the 6 months prior to the visit with one’s stable or occasional 
partner” (p=0.47). 
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Discussion 
This study conducted in HIV-HCV coinfected IDUs shows that the continued high level of 
sharing of injecting equipment remains a public health concern because of continuing 
concerns about the transmission of blood borne diseases, especially HIV and HCV.  
The proportion of IDUs who reported distributive sharing is lower than that of IDUs who 
reported borrowing equipment. From a public health perspective and a coinfected prevention 
viewpoint, it is important to differentiate between borrowing and lending among HIV-infected 
patients. This result suggests that HIV-HCV coinfected IDUs are to take more personal risks 
in terms of potential exposure to HCV re-infection or super-infections (Currie et al., 2008; 
van de Laar & Likatavicius, 2009) than they are to expose others to HCV risk by lending their 
injecting equipment. This behavior emphasizes the strategies used by IDUs to protect their 
community from HIV transmission by “informed altruism” (Des Jarlais et al., 2004) and the 
responsibility of IDUs (Rhodes et al., 2007) toward others. Interestingly, during the cohort 
follow-up, more than half of the IDUs studied had stopped injecting drugs (Bouhnik et al., 
2004).   
 
In our study, younger age, unemployment and recent cocaine use were risk factors associated 
with distributive sharing at least once in the previous six months. In most international 
literature, cocaine use is an important indicator of risky injecting (Compton, Lamb, & 
Fletcher, 1995; Reynaud-Maurupt et al., 2000; Santibanez et al., 2005)as it requires more 
frequent injections than other drugs, such as heroin (Patrick et al., 2001), and particularly 
exposes IDUs to the risk of HIV and hepatitis transmission (Guadagnino et al., 1995).  
Increasingly frequent cocaine injection can also lead to other infectious risks, like abscesses 
or other bacterial infections (Guadagnino et al., 1995; V. Hope, Kimber, Vickerman, 
Hickman, & Ncube, 2008; V. D. Hope, Marongiu, Parry, & Ncube, 2010).  HIV-HCV  
coinfected IDUs are weakened and more susceptible to exposure to infectious complications 
due to sharing (Mertz, Viktorin, Wolbers, Fluckiger, & Battegay, 2009). This result also 
emphasizes the urgent need to associate HR measures with the development of new 
pharmacological treatment for stimulant dependence.  
 
Age is also an important factor. Previous studies have shown that younger IDUs are more 
likely to engage in high-risk behaviors (Deren, Kang, Colon, Andia, & Robles, 2004). Young 
people may tend to take more risks due to lack of information and shorter history and 
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experience of drug injection. It is possible that there the “generation gap” factor also plays a 
role. Older IDUs lived during a time when AIDS decimated their circle of relationships and 
generated within them the feeling that they are “survivors" (Nord, 1997). There is a certain 
sense of guilt for staying alive and they pay particular attention to protecting themselves and 
others by minimizing risk-taking.  
 
Trust in one’s physician was also found to be associated with a reduced likelihood of 
distributive sharing. 
Since the onset of the AIDS epidemic, published studies have shown the difficult interaction 
between patients and physicians, particularly when the patient is an IDU (Hindler et al., 1996) 
and/or HIV-positive.   
Although a delay in access to ART was observed for IDUs when ART first became available 
to HIV-infected persons (Carrieri et al., 1999), today in France, access to ART for IDUs has 
considerably increased, largely due to the rapid scale-up of OST mainly through primary care, 
which improves patients' behavioral stabilization and rehabilitation (Spire, Lucas, & Carrieri, 
2007). Even if recent studies have shown that HIV-positive IDUs often report having suffered 
discrimination from health professionals and have poorer adherence to ART (Peretti-Watel, 
Spire, Lert, & Obadia, 2005), the implementation of OST as a HR tool in primary care is 
likely to have fostered the dialogue between doctors and patients regarding injection and at-
risk practices. This has probably contributed to improve the overall quality of the relationship 
between HIV-infected IDUs and their physicians.  
 
International literature has also shown that engaging in HIV care has a positive impact on the 
decrease of injecting drug use among HI-HCV co-infected IDUs (Bouhnik et al., 2004; Smit 
et al., 2006).  
It is possible that access to HIV or HCV care, through a more regular and trustful relationship 
with their HIV physicians can be considered by some patients as a unique opportunity to 
switch from a “drug user” status to that of an individual followed-up for his/her HIV. This 
new identity makes some IDUs pay particular attention to their general health and also 
provides them the opportunity to reduce or renounce injection practices, or to inject only in 
safe contexts, thus minimizing the risk of transmission of blood borne diseases (Bouhnik et al. 
2004).  
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It is important to note that HIV-HCV co-infected IDUs in France can be followed-up by 
multiple care providers (primary care physicians, HIV physicians, psychiatrists, 
hepatologists). However, the quality of the relationship may be different depending on the 
specialty of the physician, probably due to fear of judgment or stigma. For instance, it has 
been shown that HIV-HCV co-infected patients tend to underreport alcohol use to their 
hepatologist(Roux et al., 2011). HIV and primary care physicians in France were the first who 
provided care and prevention counselling for IDUs and were therefore the less judgmental. It 
is not surpriing that HIV physicians may have a better relationship with their patients, and that 
such patients are more sensitive to their counselling and adopt harm reduction practices.   
 
At any rate, this result demonstrates the importance of strengthening the dialogue and the 
therapeutic alliance between physicians (HIV or primary care physician) and their IDU 
patients. Specific training and collaborations with specialists in addiction is sometimes 
required (Ireland & McLeod, 1995). Such collaborations may modify the perception that 
physicians may have regarding their IDU patients, often perceived as “liars and manipulators” 
(George & Martin, 1992; McGillion, Wanigaratne, Feinmann, Godden, & Byrne, 2000). 
 
This result has also important implications in terms of clinical management but also policy 
repercussions in terms of HR in the IDU community. In a meta-analysis, (Martin, Garske, & 
Davis, 2000) a consistent, positive and moderately sized relationship between therapeutic 
alliance and treatment outcomes was found, and a review of recent studies (Meier, Donmall, 
Barrowclough, McElduff, & Heller, 2005; Meier, Donmall, McElduff, Barrowclough, & 
Heller, 2006) suggested that the trust in one’s physician plays an important role in predicting 
drug treatment outcomes.   
 
In interpreting these findings, certain limitations should be acknowledged. Firstly, in studies 
concerning self-reported at-risk practices, it is important to consider possible social 
desirability bias. For an HIV-positive person, distributive sharing is a very sensitive subject 
because there is a tendency to stigmatize lending behaviors. Though the validity and 
reliability of self-reports about drug use and risk practices have been established in studies 
using similar methods for data collection and processing (Darke, 1998; Latkin & Vlahov, 
1998), the risk of under-reporting for social desirability bias exists. This risk could result in a 
unidirectional misclassification of individuals lending their injecting equipment and therefore 
in a possible underestimation of the associations found. The study was also conducted with a 
Page 11 of 15
http://mc.manuscriptcentral.com/ac-phm-vcy
Health Sciences
For Peer Review Only
 9 
  
  
very specific population, i.e. HIV-HCV co-infected IDUs receiving hospital-based outpatient 
clinical care for their HIV disease. Because access to care in France is free, we assume that 
the study group may be representative of the wider HIV-infected population of IDUs.   
 
Conclusions 
Our study emphasized that high-risk behaviors are not only related to characteristics of 
patients but imply a strong relation with the social environment of IDUs (Rhodes, 2009). 
Promoting the dialogue between doctors and their opioid dependent/HIV/HCV patients can 
improve HIV and HCV prevention among IDUs. 
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